Accepted for/Published in: JMIR Public Health and Surveillance
Date Submitted: Sep 16, 2024
Open Peer Review Period: Jan 28, 2026 - Mar 25, 2026
Date Accepted: May 2, 2025
(closed for review but you can still tweet)
A Mathematical Framework to Estimate Chronic Hepatitis B Prevalence and Undiagnosed Proportion in Canada, 2007-2021
ABSTRACT
Background:
Chronic hepatitis B (CHB) remains a significant health burden for at least a hundred thousand Canadians. The government of Canada has endorsed the Global Strategy to eliminate hepatitis as a public health threat by 2030, but effectively targeting public health interventions is complicated by the silent nature of the disease, which can remain asymptomatic for decades.
Objective:
This study develops a framework to estimate the prevalence of chronic hepatitis B and the proportion of the infected population that remains undiagnosed. We apply the proposed method to national data from Canada, from 2007 to 2021.
Methods:
We infer the prevalence and undiagnosed proportion of CHB by fitting a mathematical state-transition model, based on the natural history of chronic hepatitis B, to observed CHB-related events.
Results:
We estimate the national prevalence of CHB in Canada in 2021 to be 0.308% (95% CI: 0.252% - 0.363%). The corresponding percentage of undiagnosed cases was estimated to be 33.9% (95% CI: 22.7% - 45.1%).
Conclusions:
The estimates of CHB prevalence obtained via our method are in line with previous estimates obtained from national seroprevalence studies. More specialized estimates, stratified by province or age cohort, may be achievable with detailed health administrative data.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.